Join to View Full Profile
2950 Cleveland Clinic BlvdWeston, FL 33331
Phone+1 954-659-5840
Fax+1 954-659-5833
Dr. Nagarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am board certified in Internal Medicine, Medical Oncology and Hematology
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2001 - 2004
West Suburban Medical CenterResidency, Internal Medicine, 1999 - 2001
Rush University Medical CenterInternship, Internal Medicine, 1998 - 1999
Adichunchanagiri Institute of Medical SciencesClass of 1996
Certifications & Licensure
FL State Medical License 2015 - 2026
WV State Medical License 2004 - 2017
IL State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Publications & Presentations
PubMed
- Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.Stacey A Cohen, Vasily N Aushev, George Laliotis, Iktej S Jabbal, Arun Nagarajan
Annals of Surgery. 2025-08-07 - 2 citationsNeoadjuvant chemotherapy improves overall survival in stage III but not in stage II colon cancer: A propensity score-matched analysis of the National Cancer Database.Nir Horesh, Sameh Hany Emile, Michael R Freund, Zoe Garoufalia, Rachel Gefen
Surgery. 2025-07-01 - Evaluating survival outcomes and treatment recommendations in resectable gastric cancer.Saad Sabbagh, Iktej Singh Jabbal, María Herrán, Mohamed Mohanna, Sindu Iska
Scientific Reports. 2025-01-22
Journal Articles
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Committees
- Hereditary Pancreatic cancer PCO panel, ASCO 2016 - Present
Research History
- Co-Principal Investigator for ECOG trials at Charleston Area Medical Center2004 - 2016
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
